.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX44_Aflibercept.Aflibercept

Information

Aflibercept is a recombinant fusion protein acting as a decoy receptor for vascular endothelial growth factor (VEGF), inhibiting angiogenesis. It is approved for the treatment of various forms of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and certain cancers, including metastatic colorectal cancer. It is currently marketed under trade names such as Eylea (for ophthalmic use) and Zaltrap (for oncological use).

Pharmacokinetics

Pharmacokinetic parameters in cancer patients after intravenous administration of aflibercept (Zaltrap), as reported in adult men and women with metastatic colorectal cancer.

References

1. Thai, HT, et al., & Comets, E (2011). A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. British journal of clinical pharmacology 72(3) 402–414. DOI:10.1111/j.1365-2125.2011.04015.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21575034

2. Syed, YY, & McKeage, K (2015). Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs 75(12) 1435–1445. DOI:10.1007/s40265-015-0444-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26220913

3. Yoshino, T, et al., & Ohtsu, A (2013). A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational new drugs 31(4) 910–917. DOI:10.1007/s10637-012-9895-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23179335

Revisions

• 06/2025 initial generated model